Harmony Biosciences Holdings Inc (HRMY) announced better-than-expected financial results for the third quarter of fiscal 2025. The company reported earnings per share (EPS) of $0.87, surpassing Wall Street's consensus estimate of $0.86 by $0.01. Revenue matched expectations at $0.2 billion.
The move underscores Harmony's solid operational performance in a competitive pharmaceutical landscape. The company is focused on developing therapies for neurological disorders, with its flagship product WAKIX (pitolisant) addressing excessive daytime sleepiness in pediatric narcolepsy patients.
Harmony will host an earnings conference call to discuss these results and share further insights on business performance. Investors should review the full earnings release and management commentary for context on the quarter’s performance and future outlook.
As of November 8, 2025, Harmony Biosciences holds a market cap of $1,817.17 million and a trailing P/E ratio of 10.04. The company is set to report its next earnings on August 2, 2026, with an EPS estimate of $0.969 and revenue expectations of $0.2 billion.